Shorts: FDA Approval of Rasonque: The First Broad RAS-Targeted Therapy in Pancreatic Cancer
The FDA has approved Rasonque (daraxonrasib), the first targeted therapy designed to directly inhibit RAS, the protein driving the vast majority of pancreatic cancers. In this episode, we break down how this once-daily oral RAS inhibitor works, the Phase 3 data that nearly doubled overall survival compared with chemotherapy, and who qualifies under the new label.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.